Skip to Main Content

++

INTRODUCTION

++

besifloxacin (be-si-flox-a-sin)

Besivance

Classification

Therapeutic: anti-infectives

Pharmacologic: fluoroquinolones

++
Indications
++

Treatment of bacterial conjunctivitis.

++
Action
++

Inhibits bacterial DNA synthesis by inhibiting DNA gyrase. Therapeutic Effects: Death of susceptible bacteria with decreased symptoms and sequelae of bacterial conjunctivitis. Spectrum: Active against CDC coryneform group G, Corynebacterium pseudodiphtheriticum, C. striatum, Haemophilus influenzae, Moraxella lacunata, Staphylococcus aureus, S. epidermidis, S. hominis, S. lugdunensis, Streptococcus mitis group, Str. oralis, Str. Pneumoniae, and Str. Salivarius.

++
Adverse Reactions/Side Effects
++

CNS: headache. EENT: conjunctival redness, blurred vision, eye irritation, eye pain, eye pruritus.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Monitor eye pain, itching, and inflammation to help document whether drug therapy is successful in resolving bacterial conjunctivitis.

  • Watch for any new or increased eye reactions, including pain, redness, irritation, itching, or blurred vision. Report severe or worsening eye reactions to the physician.

++
Patient/Client-Related Instruction
++

  • Check that the patient and family or caregivers understand ophthalmic application procedures and adhere to the recommended dosing schedule.

  • Instruct patient and family/caregivers to report other troublesome side effects such as severe or prolonged headache.

++
Pharmacokinetics
++

Absorption: Minimal absorption follows ophthalmic use.

++

Distribution: Unknown

++

Metabolism and Excretion: Unknown

++

Half-life: 7 hr

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE

ROUTE ONSET PEAK DURATION
Ophthalmic unknown unknown 6–12 hr

++
Contraindications/Precautions
++

Contraindicated in: Contact lens use.

++

Use Cautiously in: OB: Use during pregnancy only if potential benefit justifies potential risk to fetus; Lactation: Use cautiously during lactation; Pedi: Safe use in children <1 yr not established.

++
Interactions
++

Drug-Drug: None noted

++
Route/Dosage
++

Ophth (Adults and Children ≥1 yr): 1 drop in affected eye(s) 3 times daily (4–12 hr apart) for 7 days.

++
Availability
++

Ophthalmic suspension: 0.6% 5 mL in 7.5-mL bottle.

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.